Revolution Medicines
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell RVMD and other ETFs, options, and stocks.About RVMD
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway.
CEOMark A. Goldsmith
CEOMark A. Goldsmith
Employees534
Employees534
HeadquartersRedwood City, California
HeadquartersRedwood City, California
Founded2004
Founded2004
Employees534
Employees534
RVMD Key Statistics
Market cap15.38B
Market cap15.38B
Price-Earnings ratio-15.23
Price-Earnings ratio-15.23
Dividend yield—
Dividend yield—
Average volume2.15M
Average volume2.15M
High today$80.44
High today$80.44
Low today$78.05
Low today$78.05
Open price$78.90
Open price$78.90
Volume2.24M
Volume2.24M
52 Week high$81.49
52 Week high$81.49
52 Week low$29.17
52 Week low$29.17
Stock Snapshot
The current Revolution Medicines(RVMD) stock price is $79.89, with a market capitalization of 15.38B. The stock trades at a price-to-earnings (P/E) ratio of -15.23.
On 2025-12-13, Revolution Medicines(RVMD) stock traded between a low of $78.05 and a high of $80.44. Shares are currently priced at $79.89, which is +2.4% above the low and -0.7% below the high.
The Revolution Medicines(RVMD)'s current trading volume is 2.24M, compared to an average daily volume of 2.15M.
In the last year, Revolution Medicines(RVMD) shares hit a 52-week high of $81.49 and a 52-week low of $29.17.
In the last year, Revolution Medicines(RVMD) shares hit a 52-week high of $81.49 and a 52-week low of $29.17.
Analyst ratings
100%
of 21 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own RVMD. This list is generated using Robinhood data, and it’s not a recommendation.